Tag : Mercks

Latest News

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy for Patients With Locally Recurrent Unresectable or Metastatic Triple‑Negative Breast Cancer Whose Tumors Express PD-L1 (CPS ≥10)

Newsemia
KENILWORTH, N.J.–(BUSINESS WIRE)—- $MRK #MRK–FDA Approves KEYTRUDA Plus Chemotherapy for Patients With Locally Recurrent Unresectable or Metastatic TNBC Whose Tumors Express PD-L1 (CPS ≥10) Source...
Latest News

Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Distant Metastasis or Death by 40% Versus Placebo as Adjuvant Treatment in Resected, High-Risk Stage III Melanoma

Newsemia
KENILWORTH, N.J., & BRUSSELS–(BUSINESS WIRE)—- $MRK #MRK–Merck’s KEYTRUDA Reduced the Risk of Distant Metastasis or Death by 40% Versus Placebo as Adjuvant Treatment in Resected,...
Latest News

Pivotal RESTORE-IMI 2 Phase 3 Study of Merck’s RECARBRIO™ (imipenem, cilastatin, and relebactam) in Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Met Primary Endpoint

Newsemia
KENILWORTH, N.J.–(BUSINESS WIRE)—- $MRK #MRK–Pivotal RESTORE-IMI 2 Phase 3 Study of Merck’s RECARBRIO™ in Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia Met Primary Endpoint Source link...
Latest News

Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Statistically Significant Increase in Pathological Complete Response Versus Chemotherapy as Neoadjuvant Therapy in Early-Stage Triple-Negative Breast Cancer (TNBC)

Newsemia
KENILWORTH, N.J.–(BUSINESS WIRE)—- $MRK #ESMO19–KEYTRUDA Plus Chemotherapy Showed Statistically Significant Increase in Pathological Complete Response vs Chemotherapy as Neoadjuvant Therapy in TNBC Source link...
Latest News

New Phase 2 Clinical Trial Results Continue to Demonstrate Potential Clinical Benefit of IMV’s DPX-Survivac in Combination with Merck’s Keytruda in Patients with DLBCL

Newsemia
DARTMOUTH, Nova Scotia–(BUSINESS WIRE)–IMV Inc. (Nasdaq:IMV; TSX:IMV), a clinical stage immuno-oncology corporation, today announced updated data from the ongoing investigator-sponsored SPiReL Phase 2 clinical trial...
Latest News

Results of Phase 3 Trial Evaluating Merck’s ZERBAXA® (ceftolozane and tazobactam) versus Meropenem for Treatment of Adult Patients with Ventilated Nosocomial Pneumonia (VNP) to be Presented at ECCMID 2019

Newsemia
KENILWORTH, N.J.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24MRK&src=ctag" target="_blank"gt;$MRKlt;/agt; lt;a href="https://twitter.com/hashtag/MRK?src=hash" target="_blank"gt;#MRKlt;/agt;–Phase 3 Trial Results Evaluating Merck’s ZERBAXA® vs Meropenem for Treatment of Adult Patients with Ventilated Nosocomial Pneumonia...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy